CoLucid Pharmaceuticals Inc (CLCD)

46.52
0.03 0.05
Prev Close 46.50
Open 46.50
Day Low/High 46.45 / 46.55
52 Wk Low/High 3.57 / 10.04
Volume 127.08K
Avg Volume 547.40K
Exchange
Shares Outstanding 19.28M
Market Cap 897.30M
EPS -3.80
Div & Yield N.A. (N.A)

Latest News

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of CoLucid...

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Whether The Sale Of CoLucid Pharmaceuticals, Inc. To Eli Lilly & Co. For $46.50 Per Share Is Fair To Shareholders -- CLCD

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased CoLucid Pharmaceuticals, Inc.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of CoLucid Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of CoLucid...

Robbins Arroyo LLP: Acquisition Of CoLucid Pharmaceuticals, Inc. (CLCD) By Eli Lilly And Company (LLY) May Not Be In Shareholders' Best Interests

Robbins Arroyo LLP: Acquisition Of CoLucid Pharmaceuticals, Inc. (CLCD) By Eli Lilly And Company (LLY) May Not Be In Shareholders' Best Interests

Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of CoLucid Pharmaceuticals, Inc.

CoLucid Pharmaceuticals Reaches Analyst Target Price

CoLucid Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of CoLucid Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $42.50, changing hands for $46.25/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Stocks Hold Mixed as Fed's Yellen Forecasts Series of Rate Hikes

Stocks Hold Mixed as Fed's Yellen Forecasts Series of Rate Hikes

Stocks hold mixed on Wednesday afternoon as Federal Reserve Chair Janet Yellen caps off a day filled with interest rate speculation.

Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks

Must-Know Tricks On Trading Goldman Sachs, Ford and Other Very Active Stocks

Here's how to trade some of the most active stocks on the market Wednesday.

COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes The Acquisition By Eli Lilly And Company May Be Unfair To Shareholders

COLUCID PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe Believes The Acquisition By Eli Lilly And Company May Be Unfair To Shareholders

Former United States Securities and Exchange Commission attorney Willie Briscoe is investigating potential claims against the Board of Directors of CoLucid Pharmaceuticals, Inc.

Stocks Struggle for Direction as Economic Improvements May Push Fed Moves

Stocks Struggle for Direction as Economic Improvements May Push Fed Moves

Stocks struggle for direction on Wednesday as a strengthening U.S. economy reinforces the chances of several rate hikes this year.

Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost

Stock Futures Inch Higher as Citigroup, Goldman Sachs Get Trading Boost

Stock futures inch higher as Citigroup and Goldman Sachs join the series of banks that enjoyed a trading boost in the fourth quarter.

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

CoLucid Pharmaceuticals saw shares boost 32% ahead of the market open Wednesday.

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

Eli Lilly Acquires CoLucid Pharma, Adds Migraine Drug to Pipeline

CoLucid will be acquired for $46.50 per share, a 33% premium to the stock's closing price Tuesday.

Airline Stocks Get Airborne

I bought ProShares Ultra QQQ Trust in the premarket and sold in the first hour of trading for a profit.

Why These 4 Little-Known Stocks Have Outgunned the DJIA This Year

Why These 4 Little-Known Stocks Have Outgunned the DJIA This Year

These four stocks have soared in 2016. Here are the reasons and a look at whether there is still time to jump aboard.

CoLucid Pharmaceuticals Announces Additional Analyses Of Lasmiditan's Onset Of Action Data From SAMURAI And Supporting Non-Clinical Data

CoLucid Pharmaceuticals Announces Additional Analyses Of Lasmiditan's Onset Of Action Data From SAMURAI And Supporting Non-Clinical Data

Non-Clinical Data and Posters Presented at 5th European Headache and Migraine Trust International Congress

4 Stocks with Strong Technicals to Buy Now

4 Stocks with Strong Technicals to Buy Now

Here are four stocks with strong technicals that look poised for more upside.

Here's a Reason Why CoLucid Pharmaceuticals (CLCD) Stock Is Higher Today

Here's a Reason Why CoLucid Pharmaceuticals (CLCD) Stock Is Higher Today

CoLucid Pharmaceuticals (CLCD) announced on Friday that it intends to make a public offering of common stock.